Cover Image
市場調查報告書

抗體藥物複合體 (ADC:Antibody Drug Conjugates):全球市場及開發平台分析 (∼2020年)

Global Antibody Drug Conjugate Market & Pipeline Insight 2020

出版商 KuicK Research 商品編碼 337454
出版日期 內容資訊 英文 350 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗體藥物複合體 (ADC:Antibody Drug Conjugates):全球市場及開發平台分析 (∼2020年) Global Antibody Drug Conjugate Market & Pipeline Insight 2020
出版日期: 2015年08月17日 內容資訊: 英文 350 Pages
簡介

本報告提供抗體藥物複合體 (ADC:Antibody Drug Conjugates) 的市場相關調查、ADC的機制概要與作用機制、市場的影響因素、臨床實驗平台趨勢、已上市產品概要、開發中止、延期的產品相關分析、競爭環境與以及主要企業的簡介等彙整。

第1章 簡介:抗體藥物複合體 (ADC:Antibody Drug Conjugates)

第2章 ADC的機制

第3章 全球ADC市場:概要

  • 目前市場方案
  • ADC的臨床實驗平台概要

第4章 全球ADC市場:動態

  • 理想的市場參數
    • R&D
    • 強力的臨床實驗平台
    • 疾病表現率的增加
    • 更佳治療的需求
  • 商業化的課題

第5章 全球ADC市場:未來展望

第6章 全球ADC的臨床實驗平台:企業、適應症、各階段

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第7章 已上市ADC的臨床性考察

  • Abatacept (Orencia®, Orencia® IV & Orencia® SC)
  • Belatacept (Nulojix®)
  • Brentuximab Vedotin (Adcetris®)
  • Gemtuzumab Ozogamicin (Mylotarg®)
  • Ibritumomab Tiuxetan (Zevalin® & Zevamab®)
  • Mifamurtide (Junovan™ & Mepact®)
  • Satumomab (OncoScint CR/OV®)
  • Trastuzumab Emtansine (Kadcyla®)

第8章 開發中止、延期的ADC的臨床性考察

  • 沒有開發情形報告
  • 中止
  • 撤出市場
  • 延期

第9章 競爭環境

  • AbbVie
  • AbGenomics Corporation
  • Astellas Pharma Inc.
  • AREVA Med
  • AREVA Med
  • Biogen Idec
  • Biotest
  • Bristol-Myers Squibb
  • Celldex Therapeutics Inc
  • Helix BioPharma
  • IBC Pharmaceuticals
  • ImmunoGen
  • Immunomedics
  • Merck
  • Merrimack Pharmaceuticals
  • Millennium
  • Nordic Nanovector
  • Novartis
  • PDL BioPharma
  • Progenics Pharmaceuticals
  • Roche
  • Seattle Genetics
  • Stem CentRx
  • UCB
  • Viventia Biotechnologies
  • Xenikos

圖表

目錄

Pharmaceutical companies are trying to develop better therapeutics in order to overcome large unmet medical necessities. Currently available therapeutics suffers from various caveats like low specificity, low potency and severe adverse effects. This scenario has caused the pharmaceutical companies to develop therapeutics that can succeed these limitations. They have been able to overcome these problems and improve their medical conditions by commercializing ADC. They are rapidly gaining acceptance across the globe as they offer superior pharmacological efficiency along with minimized side effects. Most of the success has been found in the field of cancer segment where they have been able to produce superior pharmacological results as compared to other cancer therapeutics available in the market. They are also expected to be introduced for other disease categories in coming years due to which their market shares would increase in coming years.

ADC are compatible with other therapeutics which helps in increasing their efficacy of disease treatment. Investigators are trying to find solution to this issue by improving their drug design by incorporating target specific capabilities. Some targeted ADC have been introduced in market and similar features are expected to be incorporated in ADC under development. This will help in increasing their acceptance rates among patients by reducing specific side effects. However, cost-effectiveness is one the biggest question in front of ADC for various malignancies. They are at nascent stages of industry life cycle due to which high prices are expected to be persisted for some years. This fact is the potential commercial hindrance in front of ADCs as only few patients with sufficient financial backup would be able to include them in their regular therapeutic regime.

Research and development of ADC has gained lots of attention in past years due to their capability to treat various cancers. Lung cancer, breast cancer, ovarian cancer and other cancers are categorized as solid cancers which have high patient base. In case of solid malignancies it has been found that limited number of ADC are internalized and others are wasted due to limited number of receptors on the cell surface. A new approach is being studied in which chemically triggered release of drug from ADC is being developed. In this way, efficacy of the ADC would increase and they would be able to eliminate cancerous cells with high efficacy. This type of ADC has not been marketed across the globe and this segment largely remains untouched showing significant marketing opportunities.

ADC for hematological malignancies have been marketed and their clinical pipeline is also quite strong. Investigators have found that certain antigens are over expressed in hematological malignancies as compared to other malignancies. CD19, CD22, CD25, CD30, CD33 and others are being investigated. They would be used for developing ADC for Hodgkin lymphoma, NHL, ALCL and other hematological malignancies. On the other hand, HER2 has been targeted for developing breast cancer ADC and other targets are also being explored. For instance, Epidermal Growth Factor Receptor Variant III (EGFRVIII) is being explored for brain cancer. Similarly other malignancies like, prostate cancer, kidney cancer, lung cancer and other cancers are being investigated in clinical trials. With time, it is expected that investigators would be able to find more targets putatively associated with malignancies. This fact shows that market size of ADCs are going to increase several folds in coming years.

" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:

  • Global Antibody Drug Conjugates Market Overview
  • Mechanism of Antibody Drug Conjugates
  • Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
  • Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
  • Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
  • Antibody Drug Conjugates Patent Analysis
  • Global Antibody Drug Conjugates Market Future Prospects

Table of Contents

1. Introduction to Antibody Drug Conjugates

2. Mechanism of Antibody Drug Conjugates

3. Global Antibody Drug Conjugates Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Antibody Drug Conjugates Clinical Pipeline Overview

4. Global Antibody Drug Conjugates Market Dynamics

  • 4.1 Favorable Market Parameters
    • 4.1.1 Research & Development
    • 4.1.2 Strong Clinical Pipeline
    • 4.1.3 Increasing Disease Incidences
    • 4.1.4 Demand for Better Therapeutics
  • 4.2 Commercialization Challenges

5. Global Antibody Drug Conjugates Market Future Prospects

6. Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Phase-I
  • 6.4 Phase-I/II
  • 6.5 Phase-II
  • 6.6 Phase-II/III
  • 6.7 Phase-III

7. Marketed Antibody Drug Conjugates Clinical Insight

  • 7.1 Abatacept (Orencia®, Orencia® IV & Orencia® SC)
  • 7.2 Belatacept (Nulojix®)
  • 7.3 Brentuximab Vedotin (Adcetris®)
  • 7.4 Gemtuzumab Ozogamicin (Mylotarg®)
  • 7.5 Ibritumomab Tiuxetan (Zevalin® & Zevamab®)
  • 7.6 Mifamurtide (Junovan™ & Mepact®)
  • 7.7 Satumomab (OncoScint CR/OV®)
  • 7.8 Trastuzumab Emtansine (Kadcyla®)

8. Discontinued & Suspended Antibody Drug Conjugates Clinical Insight

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Market Withdrawal
  • 8.4 Suspended

9. Competitive Landscape

  • 9.1 AbbVie
  • 9.2 AbGenomics Corporation
  • 9.3 Astella Pharma
  • 9.4 AREVA Med
  • 9.5 AREVA Med
  • 9.6 Biogen Idec
  • 9.7 Biotest
  • 9.8 Bristol-Myers Squibb
  • 9.9 Celldex Therapeutics Inc
  • 9.10 Helix BioPharma
  • 9.11 IBC Pharmaceuticals
  • 9.12 ImmunoGen
  • 9.13 Immunomedics
  • 9.14 Merck
  • 9.15 Merrimack Pharmaceuticals
  • 9.16 Millennium
  • 9.17 Nordic Nanovector
  • 9.18 Novartis
  • 9.19 PDL BioPharma
  • 9.20 Progenics Pharmaceuticals
  • 9.21 Roche
  • 9.22 Seattle Genetics
  • 9.23 Stem CentRx
  • 9.24 UCB
  • 9.25 Viventia Biotechnologies
  • 9.26 Xenikos

List of Figures

  • Figure 1-1: Properties of Antibody Drug Conjugates
  • Figure 1-2: Components of Antibody Drug Conjugates
  • Figure 1-3: Types of Linkers
  • Figure 1-4: Limitations of Antibody Drug Conjugates
  • Figure 2-1: Mechanism of Brentuximab Vedotin
  • Figure 2-2: Mechanism of Trastuzumab Emtansine
  • Figure 3-1: Global Antibody Drug Conjugate Market (US$ Billion), 2014-2020
  • Figure 3-2:Global Adcetris Sales (Million US$), 2016-2020
  • Figure 3-3: Global Kadcyla Sales (Million US$), 2016-2020
  • Figure 3-4: Antibody Drug Conjugates Pipeline by Phase (%), 2015
  • Figure 3-5: Antibody Drug Conjugates Pipeline by Phase (Number), 2015
  • Figure 3-6: No Development Reported Antibody Drug Conjugates Pipeline by Phase (%), 2015
  • Figure 3-7: No Development Reported Antibody Drug Conjugates Pipeline by Phase (Number), 2015
  • Figure 3-8: Discontinued Antibody Drug Conjugates Pipeline by Phase (%), 2015
  • Figure 3-9: Discontinued Antibody Drug Conjugates Pipeline by Phase (Number), 2015
  • Figure 3-10: Suspended Antibody Drug Conjugates Pipeline by Phase (%), 2015
  • Figure 3-11: Suspended Antibody Drug Conjugates Pipeline by Phase (Number), 2015
  • Figure 4-1: Antibody Drug Conjugates Market Favorable Parameters
  • Figure 9-1:AbGenomics-Clinical Pipeline
  • Figure 9-2: Celldex Clinical Pipeline
  • Figure 9-3: Merck Clinical Pipeline
  • Figure 9-4: Merrimack Clinical Pipeline
  • Figure 9-5: Millennium Clinical Pipeline
  • Figure 9-6: Novartis Clinical Pipeline
  • Figure 9-7: Progenics Clinical Pipeline
  • Figure 9-8: Roche Clinical Pipeline
  • Figure 9-9: Seattle Genetics Clinical Pipeline
  • Figure 9-10: Viventia Clinical Pipepline

List of Tables

  • Table 2-1: Antibody Drug Conjugates under Development
  • Table 3-1: Antibody Drug Conjugates Approved Till Date, 2015
  • Table 3-2: Drugs for Treatment of HER2-Positive Breast Cancer
Back to Top